How a Swan-Ganz Catheter Works and Who Still Needs One

A Swan-Ganz catheter is a thin, flexible tube threaded through a vein and into the pulmonary artery of the heart, where it measures pressures and blood flow that no external monitor can capture directly. Introduced in 1970, it became one of the most widely used and fiercely debated devices in critical care medicine. The catheter gives clinicians a direct window into how the heart and lungs are performing under stress, but decades of randomized trials have shown that using it routinely does not improve survival in most patients, and it carries real risks. Its story is less about the device itself than about a hard lesson in medicine: that more information does not always lead to better outcomes.

What the Catheter Actually Does

The Swan-Ganz catheter, also called a pulmonary artery catheter (PAC), is designed to measure hemodynamic pressures from inside the right side of the heart and the pulmonary vasculature. A small balloon near its tip inflates with air, allowing the catheter to “float” with the flow of blood through the right atrium, right ventricle, and into the pulmonary artery. The entire placement can happen at the bedside in a matter of minutes, even in critically ill patients, without requiring fluoroscopy or a trip to a catheterization lab.¹

Once in position, the catheter provides several key measurements. It reads pressures in the right atrium, the right ventricle, and the pulmonary artery itself. When the balloon is briefly inflated to wedge in a smaller branch of the pulmonary artery, it measures what is called the pulmonary artery wedge pressure (PAWP), which serves as an indirect gauge of pressure in the left side of the heart. In normal conditions, mean wedge pressure tracks mean left atrial pressure almost perfectly.² This matters because the left side of the heart is far harder to access directly, and left-sided filling pressure is a critical clue in diagnosing heart failure and guiding fluid management.

Beyond pressure readings, the catheter measures cardiac output, the volume of blood the heart pumps per minute. The original technique involved injecting a small bolus of cold saline and tracking how quickly the temperature change traveled downstream. Modern versions use a pulsed warm thermodilution method that provides continuous cardiac output readings, along with continuous monitoring of mixed venous oxygen saturation, a measure of how well the body’s tissues are extracting oxygen from the blood.³ Taken together, these measurements let a clinician calculate things like systemic vascular resistance (how hard the blood vessels are squeezing) and pulmonary vascular resistance (how much the lung vasculature resists blood flow), which help distinguish among different types of circulatory failure.

Where It Is Used in Practice

The clearest modern role for the Swan-Ganz catheter is in diagnosing pulmonary hypertension. Right heart catheterization remains the gold standard for confirming the diagnosis and for distinguishing between the two main types. Pre-capillary pulmonary hypertension, where the problem originates in the lung vessels themselves, is defined by a mean pulmonary artery pressure at or above 20 mmHg, a wedge pressure of 15 mmHg or less, and a pulmonary vascular resistance above 2 Wood units. Post-capillary pulmonary hypertension, where the problem starts with the left heart backing up pressure into the lungs, shows a wedge pressure above 15 mmHg.⁴ Getting this classification right changes the entire treatment plan, and no noninvasive test can make this distinction with enough precision to replace catheterization.

The other setting where the catheter has seen a revival is cardiogenic shock, a life-threatening state where the heart abruptly fails to pump enough blood to sustain the body’s organs. In these patients, clinicians need to decide in real time whether to add mechanical circulatory support devices, which drugs to use, and how aggressively to give or withhold fluids. Emerging evidence suggests that using a PAC in cardiogenic shock is associated with lower mortality and fewer in-hospital cardiac arrests, likely because the hemodynamic data help guide those high-stakes decisions more precisely.⁵ A large multicenter study of cardiac intensive care units found that use of mechanical circulatory support and heart failure were the patient-level factors most strongly linked to catheter use, reflecting a shift toward more selective deployment in patients who are sickest and most likely to benefit from continuous hemodynamic data.⁶

The Controversy That Changed Critical Care

For the first two decades after its introduction, the Swan-Ganz catheter spread through intensive care units with remarkable speed. It seemed obvious that having precise hemodynamic numbers would lead to better treatment decisions. Clinicians used it freely in heart failure, sepsis, acute lung injury, major surgery, and a wide range of other critically ill populations. By the 1990s, concerns were mounting that the catheter was being overused, inserted without a clear plan for how the data would change management, and potentially causing harm through its complications.⁷

The landmark ESCAPE trial tested the catheter head-to-head against clinical judgment alone in patients hospitalized with severe heart failure. The results were sobering. There was no difference in the primary outcome of days alive and out of the hospital over six months, no difference in mortality, and no difference in length of hospital stay. What was different was the rate of in-hospital adverse events: roughly 22% in the catheter group compared with about 12% in the group managed without it.⁸ In other words, the extra information did not translate into better outcomes, and patients paid a price for having the catheter inserted.

The ESCAPE trial was not alone. A meta-analysis pooling data from randomized trials across multiple critical care populations reached the same conclusion: routine catheter use did not improve survival.⁹ These results forced a fundamental rethinking in critical care. The catheter did not become useless overnight, but the era of inserting one in nearly every ICU patient was over.

What Can Go Wrong

The risks of a Swan-Ganz catheter range from relatively minor to catastrophic. Because it sits inside the heart and pulmonary vasculature, there are opportunities for harm at every stage. Infection is a concern with any central venous line left in place for days. Arrhythmias, particularly ventricular ectopy, are common during insertion as the catheter tip passes through the right ventricle and irritates the heart muscle. Most of these rhythm disturbances are brief and self-resolving, but sustained arrhythmias occasionally require treatment.

The most feared complication is pulmonary artery rupture. A study tracking over 32,000 catheter insertions found a rupture rate of about 0.031%. All ten patients who suffered rupture presented with coughing up blood, and half had underlying pulmonary hypertension. Twenty percent were on blood-thinning medications at the time, and most of the ruptures in surgical patients happened while they were still in the operating room.¹⁰ While rare, pulmonary artery rupture carries a high mortality rate and is one reason clinicians now think carefully before placing a catheter in patients whose pulmonary pressures are already elevated.

There are also subtler harms. Every additional line and device in an ICU patient adds nursing workload and complexity, introduces new sources of potential error in reading and interpreting the numbers, and can anchor clinicians to data points that may not accurately reflect what is happening physiologically, as discussed below.

When the Numbers Lie

One of the underappreciated problems with the Swan-Ganz catheter is that its measurements can mislead. The wedge pressure, the number clinicians rely on most to estimate left heart filling, assumes that intrathoracic pressure at the end of exhalation is close to atmospheric pressure. In many ICU patients, that assumption breaks down.

Patients on mechanical ventilation with positive end-expiratory pressure (PEEP), obese patients, and those with chronic obstructive pulmonary disease can all have significantly elevated intrathoracic pressure at end-exhalation. In these cases, the measured wedge pressure overestimates the true filling pressure of the left ventricle. One study found that this effect can lead to misclassification of pulmonary hypertension type, particularly causing patients with genuine pre-capillary disease to be incorrectly labeled as having post-capillary disease based on a falsely elevated wedge pressure.¹¹ The clinical consequences can be significant: a patient classified incorrectly may receive the wrong treatment entirely.

Experimental work has shown how PEEP distorts hemodynamic pressures. In a closed-chest model, increasing PEEP from 0 to 15 mmHg caused wedge pressure to rise gradually, even as cardiac output fell. In an open-chest model, by contrast, PEEP had minimal effect on wedge pressure at lower levels, but at higher levels, pulmonary artery and capillary pressures rose while wedge pressure stayed relatively stable.¹² The takeaway for clinicians is that a wedge pressure number by itself is not enough; interpreting it correctly demands accounting for the patient’s respiratory mechanics, ventilator settings, and body habitus. This interpretive complexity is one reason the catheter’s data do not automatically improve care in less experienced hands.

Noninvasive Alternatives and Their Limits

A reasonable question is whether you can get the same information without threading a catheter through the heart. Echocardiography, particularly Doppler-based methods, can estimate many of the same hemodynamic parameters noninvasively. Studies have compared echocardiographic estimates of right atrial pressure, pulmonary artery systolic pressure, wedge pressure, cardiac output, and pulmonary vascular resistance against simultaneous Swan-Ganz measurements in heart failure patients.¹³

The results are mixed. Echocardiography performs reasonably well for estimating pulmonary artery systolic pressure and can flag obvious abnormalities. But for central venous pressure, which reflects right-sided filling, neither standard two-dimensional nor three-dimensional echocardiography showed acceptable correlation with invasively measured values. A newer technique using volumetric assessment of the inferior vena cava offered a better approximation, especially when combined with other echo parameters, but the correlation (around 0.64) still fell short of what you would want for high-stakes clinical decisions.¹⁴

For pulmonary hypertension diagnosis, where precise pressure thresholds determine the classification and treatment pathway, echocardiography serves as a useful screening tool but cannot replace right heart catheterization. Current guidelines still require invasive confirmation before initiating pulmonary hypertension-specific therapies. For less precise questions, such as whether a heart failure patient is volume-overloaded, an echocardiogram may give enough information to guide management without the risks of catheterization. The choice depends on how precise the answer needs to be.

How the Catheter Has Evolved

The Swan-Ganz catheter of 2024 is not the same device that was introduced in 1970. Early versions measured only static pressures and required intermittent bolus thermodilution to estimate cardiac output, a technique that gives you a snapshot rather than a continuous reading. Modern catheters incorporate fiberoptic technology for continuous mixed venous oxygen saturation monitoring, pulsed warm thermodilution for continuous cardiac output, and in some models, real-time right ventricular ejection fraction measurement.¹⁵ This evolution from intermittent snapshots to continuous monitoring has changed what the catheter can tell you about trends over time, particularly useful in patients on rapidly changing vasopressor regimens or mechanical support.

The thermodilution technique itself has been validated against other methods. Comparisons between the standard 7-French Swan-Ganz catheter and smaller transthoracic thermistor catheters placed directly into the pulmonary artery during cardiac surgery showed nearly identical mean cardiac output values, with strong correlation across hundreds of measurements.¹⁶ The method is well established. What has changed is less about the measurement technique itself and more about what additional data streams the catheter now provides simultaneously.

The Cost Question

Beyond clinical outcomes, the economics of Swan-Ganz catheterization have been studied in several populations. A UK-based systematic review and randomized trial found no difference in ICU length of stay, hospital length of stay, or organ-support days between patients managed with and without the catheter. Their economic analysis estimated that withdrawing the PAC from routine use would save money, with a cost per quality-adjusted life year gained of about £2,985 from the withdrawal of PAC use.¹⁷

In acute lung injury, the cost picture was even more stark. A simulation study found that catheter use had a roughly 75% probability of being both more expensive and less effective, with an average cost increase of about $14,400 and a loss of 0.3 quality-adjusted life years per patient.¹⁸ For COPD patients requiring mechanical ventilation, cost-effectiveness was possible only if catheterization-driven therapy changes improved hospital survival by at least 8.7% above baseline, a threshold the evidence struggled to support.¹⁹

These economic findings reinforced the clinical trial results. In populations where the catheter does not improve outcomes, adding its direct costs (the device itself, supplies, placement time, nursing monitoring hours, management of complications) makes the cost-effectiveness equation unfavorable. The economic case, like the clinical one, favors targeted use in selected patients rather than routine deployment.

Who Still Gets One

The pattern of catheter use has shifted substantially. In the broad ICU population, the rate of Swan-Ganz insertion has declined sharply since the trial results of the early 2000s. Where it persists and in some cases has grown is in specialized cardiac intensive care settings, particularly for patients in cardiogenic shock who are being considered for or are already on mechanical circulatory support. In a large dataset of over 13,600 cardiac ICU admissions across 34 sites, heart failure and use of mechanical circulatory support were the strongest predictors of catheter placement.²⁰

This selective approach reflects a hard-won understanding. The catheter is a diagnostic and monitoring tool, not a treatment. It generates data that can inform decisions, but the data only help if the clinical team has a clear plan for how specific hemodynamic patterns will change management, and if the patient’s condition is complex enough that noninvasive assessment genuinely cannot provide the needed information. For a patient in stable heart failure, clinical exam and echocardiography usually suffice. For a patient in refractory cardiogenic shock on multiple vasopressors with a mechanical pump in place, the continuous hemodynamic profile from a PAC may be the only reliable way to titrate therapy safely.

The catheter’s trajectory in medicine is instructive beyond its own specialty. A device that seemed intuitively beneficial, that provided genuinely useful physiological data, turned out not to improve outcomes when used broadly. The information it provided was real, but the clinical system’s ability to act on that information in ways that actually helped patients was limited. The Swan-Ganz catheter did not fail because it measured the wrong things. It failed, in the broad population, because measuring the right things is not enough if the knowledge of what to do with those measurements is incomplete, inconsistent, or overwhelmed by the risks of obtaining them.